Students Research in Progress
Monday, October 14, 2024
01:00 PM–02:30 PM
Abstract
Introduction:
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are FDA-approved to reduce hemoglobin A1C and suppress appetite in patients with type 2 diabetes mellitus and obesity, respectively. Additionally, some agents within this class have gained attention for their potential benefits in reducing cardiovascular disease risk and providing renal protection. However, in January 2024, the FDA raised safety concerns regarding suicidal ideation associated with GLP-1 RA.
Research Question or Hypothesis: What are the number of post-marketing cases in FAERS and case reports in the literature of suicide/suicidal ideation associated with the use of GLP-1 RA?
Study Design: Retrospective review of the FAERSs database and systematic review of the literature.
Methods: A search of the FAERS database was conducted to identify cases of suicide and suicidal ideation cases related to the use of any GLP1-RA up to March 31,2024. In addition, a comprehensive literature search of PubMed, Embase, and the Cochrane Library up to March 7, 2024 for any case reports. Cases will be reviewed, and descriptive statistical analysis will provide a summary of demographics, treatment, and clinical outcomes.
Results: A preliminary review of the FAERS database found 524 cases of suicide or suicidal ideation linked to GLP-1 RA use, after applying exclusion criteria. Of these, 261 cases were associated with semaglutide, 113 with liraglutide, 56 with dulaglutide, 51 with exenatide, and 1 with lixisenatide. Among these cases, 55% were female, 38% male, and 7% had unspecified gender, with a median age of 52. Additionally, 61 cases from the literature were found, mostly related to liraglutide. Further analysis is underway to assess demographics, time to event, and clinical outcomes.
Conclusion: Preliminary data from the FAERS database and literature indicates that there are cases of suicide or suicidal ideation with GLP-1 RA use. While this review does not confirm a definitive association, it underscores the need for prescribers to remain vigilant about these risks.
Presenting Author
Mohammed Zaed PharmD CandidateUniversity of South Florida Health Taneja College of Pharmacy
Authors
Kyle Hitosis PharmD Candidate
University of South Florida
Huy Nguyen PharmD Candidate
University of South Florida Taneja College of Pharmacy
Bao Anh Tran PharmD, BCPS, BCCCP
University of South Florida Taneja College of Pharmacy